System, Test, Carbohydrate Antigen (ca19-9), For Monitoring And Management Of Pancreatic Cancer
Siemens Healthcare Diagnostics Inc.'s record for this product code
Recent MDR events
366 adverse event reports on file
- ATELLICA IM CA 19-9 (CA19-9)Jul 10, 2026Malfunction1219913-2026-00143
- ATELLICA IM CA 19-9 (CA19-9)Jun 26, 2026Malfunction1219913-2026-00135
- ATELLICA IM CA 19-9 (CA19-9)Jun 26, 2026Malfunction1219913-2026-00136
- ATELLICA IM CA 19-9 (CA19-9)Jun 22, 2026Malfunction1219913-2026-00123
- ATELLICA IM CA 19-9 (CA 19-9)Mar 9, 2026Malfunction1219913-2026-00054
- ATELLICA IM CA 19-9Mar 4, 2026Malfunction1219913-2026-00049
- ATELLICA IM CA 19-9Jan 1, 2026Malfunction1219913-2026-00001
- ATELLICA IM CA 19-9 (CA19-9)Nov 17, 2025Malfunction1219913-2025-00210
- ATELLICA IM CA 19-9 (CA 19-9)Oct 22, 2025Malfunction1219913-2025-00193
- ATELLICA IM CA 19-9 (CA 19-9)Oct 22, 2025Malfunction1219913-2025-00194
Recalls
9 recall events for this product code
- Open, ClassifiedSep 11, 2024
Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.
View FDA record ↗ - Open, ClassifiedSep 11, 2024
Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.
View FDA record ↗ - Open, ClassifiedSep 11, 2024
Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.
View FDA record ↗ - Open, ClassifiedSep 11, 2024
Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.
View FDA record ↗ - Open, ClassifiedSep 11, 2024
Positive bias for some samples around the CA 19-9 upper limit of normal of 35 U/m as compared to the previous lot. The sample bias observed was greatest in the Asia Pacific sample population. The observed bias is not proportional across the assay measuring interval and is less pronounced for sample results above a concentration of 110 U/mL.
View FDA record ↗ - TerminatedDec 11, 2012
Operating range of the ADVIA Centaur systems is 18C to 30C (64.4F to 86.0F), a change in room temperature may increase or decrease assay results, depending on the specific assay and ADVIA Centaur system used.
View FDA record ↗ - TerminatedJan 11, 2012
Positive bias of 14% and higher for some individual points for CA 19-9 results generated on the ADVIA Centaur CP system when they are compared to CA 19-9 assay results generated on either the ADVIA Centaur or ADVIA Centaur XP systems
View FDA record ↗ - TerminatedUnknown
CA 19-9 assay on the ADVIA Centaur CP does not meet the correlation to the CA 19-9 assay on the ADVIA Centaur/XP/XPT systems as stated in the Instructions for Use.
View FDA record ↗ - TerminatedUnknown
CA 19-9 assay on the ADVIA Centaur CP does not meet the correlation to the CA 19-9 assay on the ADVIA Centaur/XP/XPT systems as stated in the Instructions for Use.
View FDA record ↗
510(k) clearances
1 clearances for this product code